SLAM
LGND icon

Swiss Life Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Swiss Life Asset Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$621K Sell
1,964
-82
-4% -$19.3K ﹤0.01% 856
2026
Q1 		$408K Buy
2,046
+223
+12% +$44.1K ﹤0.01% 961
2025
Q4 		$345K Buy
+1,823
New +$350K ﹤0.01% 959

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Swiss Life Asset Management's LGND Position: Q2 2026 in Review

Swiss Life Asset Management reduced its Ligand Pharmaceuticals (LGND) stake by 4% in Q2 2026, selling an estimated $19.3K and leaving 1,964 shares worth $621K. The position accounts for ﹤0.01% of the portfolio, ranked #856.

Swiss Life Asset Management first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 275 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Swiss Life Asset Management held 1,964 shares of Ligand Pharmaceuticals worth $621K as of Q2 2026.
  • Swiss Life Asset Management sold 82 Ligand Pharmaceuticals shares in Q2 2026, an estimated $19.3K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Swiss Life Asset Management's portfolio in Q2 2026, its #856 holding.
  • Swiss Life Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 275 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.